Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

AUPH

Aurinia Pharmaceuticals Inc

Dec 13 • 04:00PM ET

9.37

Dollar change -0.32
Percentage change -3.30	%

Healthcare • Biotechnology • Canada • NASD

Peers: AMGN REGN VRTX ABBV GILD BIIB BMRN INCY SAGE NBIX

| Held by: IWM IWO IBB VTWO IWN VHT AVSC SBIO SPDW ONEQ

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.16	Insider Own	10.13%	Shs Outstand	143.11M	Perf Week	4.93%
Market Cap	1.30B	Forward P/E	16.38	EPS next Y	0.57	Insider Trans	9.12%	Shs Float	128.68M	Perf Month	13.16%
Income	-22.55M	PEG	-	EPS next Q	0.02	Inst Own	39.33%	Short Float	4.84%	Perf Quarter	31.42%
Sales	220.36M	P/S	5.89	EPS this Y	104.81%	Inst Trans	-1.10%	Short Ratio	4.87	Perf Half Y	65.84%
Book/sh	2.71	P/B	3.46	EPS next Y	2100.00%	ROA	-4.08%	Short Interest	6.22M	Perf Year	7.09%
Cash/sh	2.52	P/C	3.72	EPS next 5Y	-	ROE	-5.78%	52W Range	4.71 - 10.67	Perf YTD	4.23%
Dividend Est.	-	P/FCF	45.11	EPS past 5Y	6.35%	ROI	-4.90%	52W High	-12.18%	Beta	1.25
Dividend TTM	-	Quick Ratio	5.11	Sales past 5Y	3168.98%	Gross Margin	87.25%	52W Low	98.94%	ATR (14)	0.42
Dividend Ex-Date	-	Current Ratio	5.60	EPS Y/Y TTM	71.17%	Oper. Margin	-7.13%	RSI (14)	58.76	Volatility	6.34% 4.30%
Employees	300	Debt/Eq	0.23	Sales Y/Y TTM	38.72%	Profit Margin	-10.23%	Recom	1.50	Target Price	10.47
Option/Short	Yes / Yes	LT Debt/Eq	0.19	EPS Q/Q	204.68%	Payout	-	Rel Volume	1.00	Prev Close	9.69
Sales Surprise	17.90%	EPS Surprise	566.67%	Sales Q/Q	24.32%	Earnings	Nov 07 BMO	Avg Volume	1.28M	Price	9.37
SMA20	5.00%	SMA50	17.15%	SMA200	49.33%	Trades		Volume	1,278,785	Change	-3.30%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-04-22	Downgrade	Oppenheimer	Outperform → Perform
May-05-22	Resumed	Cantor Fitzgerald	Overweight	$34 → $25
Dec-10-21	Upgrade	Oppenheimer	Perform → Outperform	$33 → $31
Oct-28-21	Downgrade	Oppenheimer	Outperform → Perform	$32
Jan-25-21	Reiterated	H.C. Wainwright	Buy	$30 → $35
Nov-03-20	Reiterated	H.C. Wainwright	Buy	$34 → $28
Jun-17-20	Initiated	BTIG Research	Buy	$20
May-05-20	Initiated	Cowen	Outperform
Jan-10-20	Initiated	Jefferies	Buy	$27
Dec-16-19	Reiterated	H.C. Wainwright	Buy	$25 → $32
Mar-16-18	Reiterated	Cantor Fitzgerald	Overweight	$14 → $16
Feb-08-18	Initiated	RBC Capital Mkts	Outperform	$9
Oct-30-17	Reiterated	H.C. Wainwright	Buy	$10 → $12
May-18-17	Reiterated	H.C. Wainwright	Buy	$12 → $10
Apr-11-17	Initiated	Cantor Fitzgerald	Overweight	$14
Mar-22-17	Reiterated	FBR & Co.	Outperform	$9 → $11
Dec-30-16	Reiterated	H.C. Wainwright	Buy	$10 → $8
Aug-17-16	Reiterated	H.C. Wainwright	Buy	$7 → $10
Jun-30-16	Initiated	H.C. Wainwright	Buy	$7
May-08-15	Initiated	MLV & Co	Buy	$9

Show Previous Ratings

Dec-10-24 08:30AM	Implied Volatility Surging for Aurinia Pharmaceuticals (AUPH) Stock Options (Zacks) +14.35%
Nov-18-24 05:53PM	Aurinia Commends 2024 Updated ACR Guidelines for Screening, Treatment, and Management of Lupus Nephritis (Business Wire)
Nov-15-24 06:00AM	Aurinia Presents New Data Underscoring Critical Importance of Earlier Lupus Nephritis Detection and Intervention and Value of LUPKYNIS in Managing LN at American College of Rheumatology Convergence 2024 (Business Wire)
Nov-14-24 06:00AM	Aurinia to Participate in Jefferies London Healthcare Conference (Business Wire)
Nov-08-24 10:30AM	Aurinia slashes workforce by 45% to focus on lupus and autoimmune assets (Pharmaceutical Technology)
06:37AM	Loading…
06:37AM	Aurinia Pharmaceuticals Reports Strong Q3 Growth and Restructuring (TipRanks)
02:12AM	Aurinia Pharmaceuticals Inc (AUPH) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid ... (GuruFocus.com)
Nov-07-24 07:40AM	Aurinia Pharmaceuticals (AUPH) Q3 Earnings and Revenues Beat Estimates (Zacks) +10.90%
06:41AM	Aurinia: Q3 Earnings Snapshot (Associated Press Finance)
06:10AM	Aurinia Pharmaceuticals Appoints Craig Johnson to Board of Directors to Support Next Phase of Growth (Business Wire)
06:00AM	Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2024 Financial and Operational Results, Announces Strategic Restructuring to Sharpen Focus on Continued LUPKYNIS Growth and AUR200 Development (Business Wire)
Oct-30-24 04:05PM	Aurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 7, 2024 (Business Wire)
06:00AM	Axonis Therapeutics Announces $115 Million Series A Financing (PR Newswire)
Oct-11-24 06:00AM	Aurinia Presents New Data Highlighting Real-World Utilization and Value of LUPKYNIS® in Treating Lupus Nephritis at American Society of Nephrology Kidney Week 2024 (Business Wire)
Sep-24-24 08:10AM	Aurinia Announces Japan Approval of LUPKYNIS (Voclosporin) to Treat Lupus Nephritis (Business Wire)
06:00AM	Loading…
Sep-13-24 06:00AM	Aurinia to Participate in 2024 Cantor Fitzgerald Global Healthcare Conference (Business Wire) +6.84%
Sep-12-24 07:02PM	Significant Acquisition by TANG CAPITAL MANAGEMENT LLC in Aurinia Pharmaceuticals Inc (GuruFocus.com)
04:05PM	Aurinia Announces Board Restructuring (Business Wire)
Sep-06-24 06:32AM	Aurinia doses first subject in Phase Ia trial of AUR200 for autoimmune diseases (Clinical Trials Arena) +5.07%
Sep-05-24 06:00AM	Aurinia Announces First Participant Dosed in AUR200 Single Ascending Dose Trial (Business Wire)
Aug-28-24 06:00AM	Aurinia to Participate in H.C. Wainwright 26th Annual Global Investment Conference (Business Wire)
Aug-22-24 10:09AM	Do Options Traders Know Something About Aurinia (AUPH) Stock We Don't? (Zacks)
Aug-13-24 08:00AM	Aurinia Pharmaceuticals Shareholder Calls for CEO Peter Greenleaf, Dr. Brinda Balakrishnan, and Dr. Robert Foster to Resign from the Board (Business Wire)
Aug-01-24 07:10AM	Aurinia Pharmaceuticals (AUPH) Q2 Earnings and Revenues Beat Estimates (Zacks)
06:14AM	Aurinia: Q2 Earnings Snapshot (Associated Press Finance)
06:00AM	Aurinia Pharmaceuticals Reports Second Quarter and Six Months 2024 Financial and Operational Results (Business Wire)
Jul-19-24 06:00AM	Aurinia Pharmaceuticals to Release Second Quarter Financial and Operational Results on August 1, 2024 (Business Wire)
Jul-12-24 04:39AM	Aurinia (AUPH) Soars 6.6%: Is Further Upside Left in the Stock? (Zacks)
Jul-11-24 03:27PM	ILJIN SNT Co., Ltd. Calls on Board of Aurinia Pharmaceuticals to Honor Shareholders' Voices Expressed at the AGM (Business Wire) +6.55%
Jul-02-24 06:00AM	Aurinia to Participate in Upcoming Investor Healthcare Conferences (Business Wire)
04:46AM	Loading…
Jun-17-24 04:46AM	Strength Seen in Aurinia (AUPH): Can Its 5.6% Jump Turn into More Strength? (Zacks)
Jun-14-24 12:16PM	Aurinia Announces 2024 Annual General Meeting Results (Business Wire) +5.61%
Jun-05-24 06:00AM	Aurinia Presents Safety and Efficacy Profile of LUPKYNIS for People with Lupus Nephritis at European Alliance of Associations for Rheumatology (EULAR) Congress 2024 (Business Wire)
Jun-04-24 05:30PM	Aurinia Addresses Dubious Proposals Put Forth by Lucien Selce (Business Wire)
Jun-03-24 06:30PM	Aurinia Provides Update on Proxy Statement (Business Wire)
May-30-24 06:00AM	Aurinia Will Attend 2024 Jefferies Global Healthcare Conference (Business Wire)
May-14-24 06:00AM	Analysis Showing LUPKYNIS is a Cost-Effective Treatment for Lupus Nephritis Presented at National Kidney Foundation's Spring Clinical Meeting 2024 (Business Wire)
May-09-24 06:00AM	Aurinia Presents Data Reinforcing LUPKYNIS Safety and Efficacy for People with Lupus Nephritis at Congress of Clinical Rheumatology East 2024 (Business Wire)
May-07-24 09:55AM	How Much Upside is Left in Aurinia (AUPH)? Wall Street Analysts Think 96.51% (Zacks)
06:00AM	Aurinia Will Attend 2024 RBC Capital Markets Global Healthcare Conference (Business Wire)
May-03-24 01:02PM	Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-02-24 10:56AM	AUPH Stock Earnings: Aurinia Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
07:10AM	Aurinia Pharmaceuticals (AUPH) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
06:10AM	Aurinia: Q1 Earnings Snapshot (Associated Press Finance)
06:00AM	Aurinia Pharmaceuticals Reports First Quarter 2024 Financial and Operational Results (Business Wire)
May-01-24 06:00AM	Aurinia Underscores Enduring Commitment to People Living with Lupus Nephritis Through Innovative Advocacy and Education Initiatives for Lupus Awareness Month (Business Wire)
Apr-30-24 06:00AM	The U.S. Food & Drug Administration (FDA) Approves Updated LUPKYNIS (voclosporin) Label to include Long-Term Data from the AURORA Clinical Program (Business Wire)
Apr-16-24 10:48AM	UPDATE: New Aurinia Presentation Details at the 2024 Bloom Burton & Co. Healthcare Investor Conference (Business Wire)
Apr-15-24 06:00AM	Aurinia Pharmaceuticals to Release First Quarter Financial and Operational Results on May 2, 2024 (Business Wire)
Apr-09-24 06:00AM	Aurinia Will Attend 2024 Bloom Burton & Co. Healthcare Investor Conference (Business Wire)
Mar-17-24 05:20PM	11 Oversold Biotech Stocks To Buy Right Now (Insider Monkey)
Feb-29-24 08:30AM	Aurinia Receives Exemptive Relief from Canadian Securities Regulators for Share Repurchase Program (Business Wire)
Feb-27-24 08:30AM	Aurinia to Participate in Upcoming Investor Healthcare Conferences (Business Wire)
Feb-16-24 09:22AM	Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-15-24 07:25AM	Aurinia Pharmaceuticals (AUPH) Reports Q4 Loss, Tops Revenue Estimates (Zacks) -24.47%
06:49AM	Aurinia Pharmaceuticals Inc (AUPH) Announces Year-End Financial Results and Strategic Initiatives (GuruFocus.com)
06:32AM	Aurinia: Q4 Earnings Snapshot (Associated Press Finance)
06:19AM	UPDATE 2-Aurinia Pharma fails to sell itself; to stop trials, cut jobs, buy back shares (Reuters)
06:10AM	Aurinia to cut research after sale process fails to find a buyer (BioPharma Dive)
06:07AM	Aurinia to stop R&D on immunotherapies to focus on kidney disease drug (Reuters)
06:00AM	Aurinia Discloses 2023 Year-End Financial and Operational Results, Announces Corporate Actions Focused on Enhancing Shareholder Value (Business Wire)
Feb-08-24 10:00AM	Aurinia Pharmaceuticals (AUPH) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release (Zacks)
Feb-05-24 08:30AM	Aurinia Pharmaceuticals to Release 2023 Fourth Quarter and Full Year Financial and Operational Results on February 15, 2024 (Business Wire)
Jan-18-24 04:30PM	Kane Biotech Announces Special Meeting of Shareholders (GlobeNewswire)
Jan-05-24 06:00AM	Aurinia Provides Preliminary Unaudited Fourth Quarter and Full-Year 2023 Net Revenue Results (Business Wire)
Dec-28-23 09:40AM	Are Medical Stocks Lagging Aurinia Pharmaceuticals (AUPH) This Year? (Zacks)
Dec-20-23 06:00AM	Aurinia Submits IND Application to US Food & Drug Administration for AUR 200 (Business Wire) -6.11%
Dec-10-23 06:59AM	This Small Pharma Could Be Targeted, But Would Be Fine Alone, Too (TheStreet.com)
Nov-23-23 09:55AM	Can Aurinia (AUPH) Climb 46.13% to Reach the Level Wall Street Analysts Expect? (Zacks)
Nov-20-23 09:40AM	Is Aurinia Pharmaceuticals (AUPH) Stock Outpacing Its Medical Peers This Year? (Zacks) +7.44%
Nov-13-23 06:00AM	Aurinia Pharmaceuticals Announces Collaboration Partner Otsuka Filed New Drug Application (NDA) for LUPKYNIS (Voclosporin) in Japan (Business Wire)
Nov-07-23 10:30AM	Aurinia Presents Breadth of Data from AURORA Clinical Program Underscoring Value of LUPKYNIS (voclosporin) for Patients with Lupus Nephritis at ACR 2023 (Business Wire)
09:55AM	Wall Street Analysts See a 59.35% Upside in Aurinia (AUPH): Can the Stock Really Move This High? (Zacks)
Nov-03-23 09:40AM	Are Medical Stocks Lagging Aurinia Pharmaceuticals (AUPH) This Year? (Zacks)
08:46AM	Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-02-23 06:00PM	Aurinia Presents Breadth of Data at ASN 2023 Demonstrating Clinical Importance of LUPKYNIS for Managing Lupus Nephritis (Business Wire) +10.52%
07:50AM	Aurinia Pharmaceuticals Inc (AUPH) Reports 60% Increase in Q3 Net Product Revenue (GuruFocus.com)
07:15AM	Aurinia Pharmaceuticals (AUPH) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
06:10AM	Aurinia: Q3 Earnings Snapshot (Associated Press Finance)
06:00AM	Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2023 Financial and Operational Results (Business Wire)
Oct-26-23 03:00PM	Aurinia Response in Support of 2023 Updated EULAR Recommendations for Management of Lupus and New Treatment Paradigm for Lupus Nephritis (Business Wire)
Oct-19-23 10:31AM	CORRECTING and REPLACING Aurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 2, 2023 (Business Wire)
06:00AM	Aurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 2, 2023 (Business Wire)
Oct-16-23 09:29AM	Pfizer (PFE) Cuts 2023 Outlook as COVID Products' Demand Falls (Zacks) +5.32%
Oct-14-23 01:15PM	13 Stocks to Buy with Exponential Growth (Insider Monkey)
Oct-13-23 12:00PM	Aurinia Pharmaceuticals Announces Presentations at American Society of Nephrology (ASN) Kidney Week 2023 and 2023 American College of Rheumatology Convergence (ACR) (Business Wire)
Oct-12-23 12:13PM	Lilly (LLY) Up on NVO's Ozempic Early Success in Kidney Study (Zacks)
Oct-11-23 10:15AM	Merck's (MRK) Keytruda Early-Stage NSCLC Study Shows OS Benefit (Zacks)
Oct-09-23 11:10AM	J&J (JNJ) Seeks EU Nod for Rybrevant for First-Line NSCLC (Zacks)
Oct-06-23 09:24AM	AbbVie (ABBV) Buys Parkinson's Disease Treatment Maker (Zacks)
Oct-04-23 08:17AM	AstraZeneca (AZN) Settles Heartburn Drugs Lawsuits for $425M (Zacks)
Oct-03-23 07:43AM	Lilly's (LLY) Eczema Candidate Lebrikizumab Faces FDA Rejection (Zacks)
Sep-29-23 09:40AM	Are Medical Stocks Lagging Align Technology (ALGN) This Year? (Zacks)
Sep-27-23 09:34AM	Is it a Good Time to Invest in Aurinia Pharmaceuticals (AUPH)? (Zacks)
Sep-26-23 10:56AM	AbbVie's (ABBV) Epcoritamab Gets Approval in Europe for DLBCL (Zacks)
Sep-21-23 06:00AM	Aurinia Board of Directors Appoints Dr. Robert T. Foster as New Board Director And Enters Cooperation Agreement with Shareholder MKT Capital (Business Wire)
Sep-18-23 08:52AM	5 Stocks to Buy as Drug Industry Displays Strong Fundamentals (Zacks)
Sep-06-23 09:55AM	Wall Street Analysts Think Aurinia (AUPH) Could Surge 42.86%: Read This Before Placing a Bet (Zacks)
Aug-25-23 09:40AM	Is Aurinia Pharmaceuticals (AUPH) Stock Outpacing Its Medical Peers This Year? (Zacks)
Aug-21-23 06:00AM	Aurinia Appoints Two New Board Directors with Deep Experience in BioPharma Leadership, Commercial Strategy, Mergers and Acquisitions and Advancing Therapeutic Pipelines (Business Wire)

Aurinia Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Victoria, Canada.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
TANG KEVIN	Director	Dec 09 '24	Buy	9.09	500,000	4,545,000	8,429,500	Dec 09 04:52 PM
TANG KEVIN	Director	Dec 06 '24	Buy	9.01	400,000	3,604,000	7,929,500	Dec 09 04:52 PM
TANG KEVIN	Director	Dec 05 '24	Buy	8.91	300,000	2,673,000	7,529,500	Dec 09 04:52 PM
Bailey Jeffrey Allen	Director	Nov 11 '24	Sale	8.43	4,557	38,416	13,356	Nov 12 07:29 PM
Smith Karen L.	Director	Nov 11 '24	Sale	8.43	5,241	44,182	12,672	Nov 12 07:20 PM
Habig Scott Michael	Chief Commercial Officer	Aug 06 '24	Sale	5.31	18,249	96,902	456,338	Aug 08 04:06 PM
Balakrishnan Brinda	Director	May 21 '24	Sale	5.74	520	2,985	17,523	May 22 04:16 PM
Billen Daniel	Director	May 21 '24	Sale	5.74	5,252	30,146	28,141	May 22 04:14 PM
Jayne David R.W.	Director	May 21 '24	Sale	5.74	4,946	28,390	44,364	May 22 04:11 PM
Leversage Jill	Director	May 21 '24	Sale	5.74	5,610	32,201	12,918	May 22 04:09 PM
MacKay-Dunn R. Hector	Director	May 21 '24	Sale	5.74	5,630	32,316	18,595	May 22 04:07 PM
Greenleaf Peter	Chief Executive Officer	Mar 06 '24	Sale	5.60	126,981	711,094	1,522,114	Mar 07 04:46 PM
Miller Joseph M	Chief Financial Officer	Mar 06 '24	Sale	5.60	34,811	194,942	495,928	Mar 07 04:44 PM
Donley Matthew Maxwell	EVP, Ops & Strategy	Mar 06 '24	Sale	5.51	40,665	224,064	584,072	Mar 07 04:43 PM
Habig Scott Michael	Chief Commercial Officer	Mar 06 '24	Sale	5.60	17,777	99,551	474,587	Mar 07 04:42 PM
Robertson Stephen P.	EVP, General Counsel	Mar 06 '24	Sale	5.60	57,745	323,372	443,824	Mar 07 04:41 PM
Knappertz Volker	EVP, Research and Development	Feb 27 '24	Sale	6.10	4,930	30,073	319,128	Feb 29 04:11 PM
Knappertz Volker	EVP, Research and Development	Feb 20 '24	Sale	5.48	25,146	137,800	324,058	Feb 22 04:35 PM
Habig Scott Michael	Chief Commercial Officer	Feb 20 '24	Sale	5.48	15,867	86,951	492,364	Feb 22 04:33 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AUPH

Aurinia Pharmaceuticals Inc

Upgrade your FINVIZ experience